secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001193125-24-100902
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology R&D President Douglas Williams resigns effective April 18, 2024
--------------------------------------------------------------------------------

- Douglas Williams, Ph.D., resigned as EVP and President, Research and Development.
- Resignation effective April 18, 2024; voluntary for personal reasons.
- No disagreement with the company cited; no successor named.
- Williams' departure removes a key R&D leader in a biotech with no pipeline-stage products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312524100902/0001193125-24-100902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312524100902/d823295d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-100902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer